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I. Introduction
Germany's rise to one of the leading industrial economies during the late 19 th and early 20 th century was, among many other reasons, ascribed to its ability to innovate. In particular, Germany's success during the 'second' industrial revolution was connected to the inventions made in the fields of chemistry, pharmacy, and electrical engineering. In turn, the inventive activity was fostered by the high quality of Germany's system of higher education, the substantial governmental support for science, and -last but not least -the emergence of industrial research laboratories (Landes, 1999: 290-291; Cameron / Neal, 2003: 242-243) .
More specifically, the invention of the company-sponsored research organisation was identified as the undoubtedly greatest single contribution of the German dyestuff industry (Beer, 1959: 73) . This path-breaking organisational revolution transformed the firms from fellow-runners to market leaders in synthetic dye production. At least since Beer's observation, the research laboratories of the dyestuff industry itself had been the object of scientific research. The focus of these studies had been the development at Bayer (e.g., Beer, 1959; Meyer-Thurow, 1982; Murmann, 2006) whereas the two other major dyestuff producers, BASF and Hoechst, were much less intensively investigated (Homburg, 1992; Reinhardt 1997) . 1 Yet, the evidence of a science-based second industrial revolution is much less clear for other industries. König (1995 König ( , 1996 showed that the causality between industrial development and scientific research was opposite in electrical engineering, compared to the experience of the dyestuff industry. Electrical engineering was an industry-driven science, not a science-driven industry. In addition, Erker (1990) pointed out that professionally managed centralized research laboratories emerged during the 1920s, and not during the pre-World War I period. Before World War I, research was decentralized at the major German electrical engineering firms Siemens and AEG. Moreover, centralized research laboratories appeared at about the same time in the U.S., Germany, and other European states.
Turning to the pharmaceutical industry, findings by Wimmer (1994) show that professionally managed in-house research and development (R&D) was constricted to Bayer, whereas Hoechst procured new products from universities and only improved the production process in-house. 2 Furthermore, the traditional pharmaceutical company Schering failed to develop a R&D strategy during the pre-World War I period (Wimmer, 1994; Kobrak, 2002) . Jointly and severally, it seemed that the professionally managed centralized corporate R&D laboratory was constricted to dyestuff production. Moreover, all but one dyestuff firm -Bayer -failed to transfer the R&D organisation to the new field of pharmaceuticals. 3 A detailed case study from the pharmaceutical industry is potentially important for this debate in several respects. First of all, most studies regarding the emergence of corporate R&D focus on the dyestuff industry. This industry clearly deserves a substantial amount of attention, since industrial R&D laboratories were invented in this industry. On the other hand, dyestuffs were relatively unimportant in terms of output. In 1913, they accounted for only 3.5 percent of the value of the worldwide chemical production, whereas pharmaceuticals accounted for 17.5 percent (Ungewitter, 1931: 6) . Second, the pharmaceutical knowledge base experienced a major shift during the 1870s and 1880s. More specifically, the sources of bacteriological infections were discovered and treatments for them were developed. Moreover, it turned out that dyestuffderivatives could be used as antipyretics and analgesics. Consequently, traditional pharmaceutical firms, whose knowledge based mainly on alkaloid chemistry, were faced with a new knowledge base and with the market entry of the major dyestuff producers into the drug market. 4 Faced with this shift in general conditions, the major dyestuff and pharmaceutical firms adapted their behaviour. 5 This paper offers a detailed case study about the emergence, organisation, and development of R&D at E. Merck, the oldest pharmaceutical company in the World. 6 So far, only the expansion of the research laboratories of the German dyestuff producers Hoechst, Bayer, and BASF towards pharmaceutical research as well as R&D at the traditional pharmaceutical firm Schering had been evaluated (Wimmer, 1994; Reinhardt, 1995; Kobrak, 2002) . These case studies showed a substantial heterogeneity in the organisation of R&D: Bayer developed strong in-house research capacities, Hoechst mostly relied on long-term research co-operations with university researchers, Schering depended upon the creativity of an individual in-house researcher, and BASF left the pharmaceutical market quite soon.
Merck is an important case study for at least three reasons. First, Merck is a much older firm than Hoechst, Bayer, BASF, and Schering, which were all established during the 1860s, whereas Merck dates back to the late 17 th century and was established as a general partnership in 1827. Consequently, its learning base and organisational structure were built up during a different state of scientific knowledge. Second, Merck was a family-owned and managed firm whereas the large competitors were publicly quoted joint-stock companies, often with outside managers. Third, Merck was a major player in pharmaceutical research. Taking the number of innovative pharmaceutical products on sale in 1911/ 12 as a measure, Merck was number four on the German market (Wimmer, 1994: 228) .
By and large, our case study shows a success story. We present evidence that Merck was not captured by its traditional knowledge base or its family-based management. Jointly and severally, Merck's R&D strategy was similar to Hoechst's strategy. Merck mostly relied on external 4 Moreover, the role of small pharmacies and the distribution of drugs changed significantly after the introduction of industrial production (Wimmer, 1991) . 5
This shift in the knowledge base is comparable to the shift induced by the bio-tech revolution of the 1970s. Galambos / Sturchio (1998) evaluate the bio-tech revolution from the perspective of business history. Dominguez-Lacasa (2006) evaluates the consequences of established knowledge bases at German pharmaceutical companies for the adaptation to the new technology since the 1970s. 6
Huhle-Kreutzer (1989: 121-150) described the innovative activity of Merck from the 1830s until the 1950s from a medical-historical perspective.
researchers for the development of new products. Nevertheless, the firm had substantial in-house research capacities, which were radically re-organized in 1898 with the establishment of its central research laboratory. The main activity of this laboratory was the screening of dozens of inventions offered by outside inventors and the improvement of production processes. However, Merck's success strongly depended on a small number of blockbuster drugs. In this respect, the firm was similar to its main competitors. Moreover, Merck failed to devote substantial resources to in-house R&D. Consequently, when the supply of product innovations from outside innovators flattened during the last years preceding the Great War, Merck's innovativeness declined substantially.
The remaining parts of the paper are organized as follows. In Section II, an aggregate picture of R&D at Merck between the 1890s and World War I is depicted. Section III describes Merck's external sources of innovation, e.g., cooperation with universities and the buying of production innovations on the market for technology. Section IV presents the in-house R&D capacities of the firm. The final Section V concludes the paper.
II. The development of E. Merck
Merck's history can be traced back to 1688, when Friedrich August Merck bought the Engel-Apotheke ('Angel pharmacy') in Darmstadt, a small city south of Frankfurt. The move to industrial production was initiated in 1827 by Emanuel Merck, who founded, together with his sons Carl, Georg, and Wilhelm, the business partnership E. Merck. From the 1880s onwards, the third generation of the Merck family controlled the business. All family members were well trained to manage the company: Carl's oldest and youngest sons, Johann Heinrich Emanuel Merck and Carl Merck, received both a management education and were responsible for the commercial affairs of the company until 1897/ 98, when this activity was taken over by the chemists Louis Merck, the third brother, until his death in 1913. Georg's sons, Emanuel August Merck and Willy Merck, were responsible for the sales department and the production department , respectively. Both had received a PhD in chemistry and pharmacy before entering the firm. Willy's sons, Carl Emanuel Merck, a chemist, and Georg Merck -who had a degree in management -managed the social affairs department the large chemical firms Hoechst, Bayer, and BASF into the market for pharmaceuticals. Consequently, the competitive and technological pressure on Merck increased substantially during the 1880s and 1890s.
The path-breaking bacteriological and immunological research conducted by Louis Pasteur and Robert Koch since the 1870s resulted into the discovery of the tubercle bacillus in 1882 and the cholera bacillus one year later. 8 In a very short period thereafter, almost all infectious diseases had been identified and pharmaceutical research related to these findings started soon. In a first step, vaccines against bacteriological infections were invented, followed by the development of sero-therapy. This latter type of medical treatment was brought forward by Emil von Behring and Paul Ehrlich. 9 In 1894, they developed the first drug in this line of research, an antidiphtheric serum. In 1910, Paul Ehrlich invented the first antibiotic, Salvarasan, which was the first drug to cure syphilis and a blockbuster for Hoechst, one of Merck's main competitors.
The usefulness of dyestuffs as pharmaceuticals was discovered during the 1880s. The first major drug in this regard, the antipyretic Kairin, was originally developed in search of a new dyestuff, but launched as a drug in 1883 by Hoechst (Wimmer, 1994: 150-151) . The other German dyestuff firms followed soon with similar drugs: BASF introduced Thallin in 1885, Kalle & Co. launched Antifebrin in 1886, and Bayer rolled Phenacetin out in 1888 (Reinhardt, 1995: 253-254 These changes in the medical knowledge base made it more and more difficult for individual pharmacists to produce all known drugs by themselves. Thus, the production of pure basic chemicals as well as of ready-touse prescription and over-the-counter (OTC) drug shifted to industrial firms. Merck, for example, distributed such ready-to-use prescription and OTC drugs as 'specialities' (Patent-und Specialpräparate) to pharmacies, doctors, and consumers (Bernschneider-Reif, 2002: 53-54) . 11
In 1915, Richard Willstätter received the Nobel Prize for Chemistry. 12 MRO, F3 / 2c.
The major shifts in the scientific and organisational environment of the 1880s and 1890s are also numerically visible, in input as well as in output figures. Global input factors for a firm are the number of employees and the value of capital in use. More specifically for R&D are the number of employees and the money spent on these activities. The total number of Merck's employees increased continuously from 714 in 1895 to 1,135 in 1901, and finally to 2,082 in 1914. 13 The number of scientists employed in the central research laboratory was, on the other hand, roughly constant at about eight researchers between 1898 and World War I. Yet, the total number of researchers employed by the firm was larger, since some researchers were located in other departments of the company, for example in the bacteriological laboratory, the scientific information department, the control laboratory, and in several production units. 14 A more comprehensive picture of resources devoted to R&D can be gained by locking at the amount of money spent. A widely-used, albeit incomplete, measure of innovative output is the number of patents granted. 20 For Germany, this indicator is available from 1877 onwards, since the first unified German patent law was enacted during this year. Yet, the grant of pharmaceutical and chemical patents became much easier after the 1891 patent law reform act and the number of patents granted to these industries increased substantially thereafter. 21 Compared to the U.S. and U.K.
13
MRO F3/2a, MRO F3/5a, and MRO F3/18a. Thus, Merck was much smaller than the big chemical companies BASF, Bayer, and Hoechst, but larger than Schering (1,227 employees in 1913), Chemische Fabrik von der Heyden (1,509 employees), and J.D. Riedel (1,001 employees), see Ungewitter (1931) . 14 In 1912-14, the number of scientists in the central research laboratories of BASF, Bayer, and Hoechst was 29, 15, and 28, respectively (Reinhardt, 1997: 286, 365-366; Marsch, 2000: 66) . 15
In 2006 Grilliches (1990) reviews the usefulness of patents as an indicator for innovations. More specific for the German historical context are Grupp et al. (2002) and Metz / Watteler (2002) . 21
See Seckelmann (2005) for a detailed account of the history of Germany's patent law. On aggregate, the number of patents granted in 1893-95 was 14 percent higher than the number of patents granted in 1890-92. patent systems, four features of the German patent law were outstanding. First, a patent was granted to the person registering the patent at the patent office and not to the true inventor. Consequently, inventions made by employed inventors were granted to the firms employing them. 22 Moreover, long-term research contracts between firms and university researchers often allocated the patent to the firm. 23 Second, a detailed technical examination of the invention was made by the patent office. In addition, patent infringements were mostly settled in the period between the publication of a patent application and the grant of the patent. Therefore, patents granted represented secure property rights. 24 Third, it was compulsory to put the patent into use within three years after it was granted. Consequently, individual inventors or university professors had a strong incentive to sell or licence their patents to firms. Fourth, patenting of pharmaceutical final products was forbidden by patent law; only the production process could be patented. Moreover, even patenting of processes was quite difficult until the 1891 patent law reform. Thus, imitation of final products of competitors using slightly modified processes was common practice. 25 In turn, safeguarding final products via patenting of a set of different production processes was necessary. Patents for the chemical and pharmaceutical industries (technology classes 12 and 22) increased, on the other hand, by about 87 percent. 22
More than 60 percent of all patents were granted to firms. 23
See Section III for the case of Merck. 24
Less than 0.4 percent of the patents granted were repealed after the grant. 25
Lee (2003) showed that coexistence of innovation and imitation within one firm was common in the U.S. pharmaceutical industry until the 1940s, whereas thereafter firms were either innovators or imitators.
Merck received its first patent on 6 October 1885 (patent-no. 35,724) for a method to manufacture peptone using nucleon proteins (Löw, 1952: 47) . 26 Until the reform of the patent law in 1891, Merck's patenting activity was nearly non-existent (see Figure 1 ). From 1892 onwards, on the other hand, eight patents were on average granted to Merck annually. In addition, Merck bought 28 patents from other inventors and sold three patents on the market for intellectual property rights. As could be expected, nearly all of Merck's patents (151 out The annual flow of new patents granted to Merck or acquired by Merck resulted into a growing stock of patents held by the company. In turn, the costs of keeping the patents active increased substantially during the early 20 th century (see Figure 2 ). 28 Merck's patent stock surpassed ten in 1894 and 100 in 1905. The fees paid surpassed 5,000 Mark in 1899 and 10,000 Mark in 1906. The patent stock of the company peaked in 1907/ 08 with 117 patents in force (1907) and 14,590 Mark fees paid (1908) respectively. Thereafter, the patent stock and the fees paid declined substantially to 74 patents in force and 3,430 Mark fees paid in 1913. The patent data thus show a 26 Peptones are used as a culture medium in bacteriological research. 27
The Imperial Patent Office allocated the patent classification according to the industry of use, not according to the industry of origin. 28
Keeping a patent in force was expensive in the German Empire. The owner of a patent had to pay an annual fee, which increased from 30 Mark for the first year to 50 Mark for the second year, 100 Mark for the third year, 150 Mark for the fourth year, and so on. The fee for the 15th and final year was 700 Mark. Thus, the cumulated fee for 15 years of protection was 5,280 Mark, about 6.5 times the annual per capita income in 1913.
marked increase in innovative activity at Merck during the first years of the 20 th century, followed by a crisis of innovation during the years preceding the Great War.
R&D resources were converted into patentable innovations, and these innovations should have been used in final products sold by Merck. Therefore, resources devoted to R&D and patenting activity should be visible in output figures for R&D intensive products. In general, Merck doubled its turnover from 5.7 million Mark during the business year 1894/ 95 to 11.5 million Mark in 1902/ 03 and then again to 23 million Mark in 1912. 29 The turnover of Merck's specialities (i.e., prescription and OTC drugs) increased, on the other hand, by factor four between the turn of the century and World War I. 30 Furthermore, prescription and OTC drugs were very profitable. In 1902/ 03, Merck's total profit was 1.36 million Mark, about 11.8 percent of the annual turnover. 31 In 1912, total profits were roughly 3.9 million Mark, about 17 percent of the turnover. In 1902/ 03, about 13.1 percent of the total profits were generated by the specialities. Ten years later, in 1912, about 28.5 percent of the profits were made with these R&D intensive products. 32 This illustrates the rising importance of R&D intensive products for Merck.
As today, pharmaceutical companies generated most of the profits with a small number of blockbuster products. Table 1 shows Merck's blockbuster products. The table is derived from the product-specific accounts, which Merck kept for its most important products. The productspecific accounts include information about turnover, marketing expenditure, profits, and remuneration of outside inventors. In 1897/ 98, eleven products were separately accounted for, in 1912, 53 products were already covered by such detailed accounts. 33
29
In 1913, Bayer generated a turnover of about 22 million Mark with pharmaceuticals (Wimmer, 1994: 143) .
Hoechst's turnover with pharmaceuticals was about 4.8 million Mark in 1909 and 6.4 million Mark in 1910 (Wimmer, 1994: 185) . Schering generated a total turnover of about 16.8 million Mark in 1913 (Ungewitter, 1931 (Kobrak, 2002: 360-361) . Therefore, Merck had a faster growth of turnover and a higher profitability than Schering. 33 MRO F3/1b and MRO F3/16a. Moreover, separate accounts are available for the 27 products covered by a pharmaceutical cartel agreement. Burkert (1990) described the history of this cartel agreement. Merck's most important product was the haemostasis drug Stypticin, which generated a profit of nearly 1.2 million Mark between its launch in 1897 and the end of 1913. Dionin, a morphine derivative antitussive drug, generated profits of nearly one million Mark between its rollout in 1898 and 1913. Jodipin and Haemol were both bacteriological drugs used in fighting streptococcus, tubercle, and syphilis. Perhydrol and Magnesium perhydrol were disinfectants applied in dentistry and -in a lower concentration -as a mouthwash. Veronal, which was jointly developed and sold with Bayer, was the first barbiturate. Pyoktanin, which based on dyestuffs, was used to treat mycosis of the eye. Fibrolysin and Tannoform, finally, were used to sanitise wounds, the latter also in treatment of intestinal diseases. 34
Similar product-specific accounts were also kept at Bayer and Hoechst (Wimmer, 1994: 120-122, 185-187) . In 1897, for example, Bayer generated a turnover of 4.66 million Mark and a profit of 1.36 million Mark with its most important pharmaceuticals (Wimmer, 1994: 120) . This compares to a turnover of only 0.43 million Mark and profits of about 67,000 Mark at Merck during the business year 1897/ 98. Consequently, Merck's drug business was much smaller and less profitable during the late 1890s than Bayer's. In addition, few blockbuster products were responsible for the major part of turnover and profits at all companies. In 1909, for example, Hoechst generated about half of its pharmaceutical turnover with its two top-selling drugs, Antipyrin and Pyramidon (Wimmer, 1994: 185-186) . In a similar fashion, Merck generated 40 percent of its pharmaceutical turnover with its two blockbuster drugs Veronal and Dionin in 1909. 35 34 It is important to note that Merck made substantial profits producing more traditional products. For example, Merck's cocaine production generated a turnover of more than 1.5 million Mark and a profit of more than 400,000 Mark in 1912. 35 In 1913, Schering generated drug sales of 2.7 Million Mark, about 15.9 percent of the total sales of the company. The two most important drugs, Atophan and Urotropin, accounted for nearly three-quarters of Schering's pharmaceutical sales (Kobrak, 2002: 364) .
The above mentioned data regarding the money spend for R&D already suggested that a substantial part of the R&D expenditures was used to compensate outside inventors. Actually, Merck's top ten drugs of the pre-World War I era were all invented by outside inventors (see Table 2 ). In this respect, Merck was very similar to Hoechst: 21 out of 24 of Hoechst's high-value pharmaceuticals developed between 1883 and 1909 were invented by outsiders (Wimmer, 1994: 185) . 
III. Research collaboration and the market for technology
Until today, the collaboration of industrial firms and universities is an important component of pharmaceutical research (Chandler, 2005) . During the two decades preceding World War I, the emergence of such co-operation was fostered by Germany's patent law, which prescribed the application of a patent within three years after it was granted. Otherwise, the patent was repealed and the knowledge was available for free. Consequently, university professors and other outside inventors, who did not possess the necessary means to produce drugs on a large scale, were forced to sell or licence their patent. University professors as well as firms realized this problem in advance and often closed long-term research contracts, which allocated the right of use of a patent to the firm and a substantial remuneration to the inventor.
For example, Merck's most successful drug, Stypticin, was developed by Martin Freund, a professor of medicine in Frankfurt, during the 1890s. This drug was based on water soluble crystals being vasoconstrictive and was used as haemostasis drug. The business relationship between Merck and Freund began in February 1891, when they signed a long-term research contract. The stipulations agreed upon in this contract are typical for other contracts closed by Merck. The contract ran for at least five years, but was prolonged automatically thereafter if both parties did not terminate the agreement with a period of notice of 15 months. Merck paid a fixed amount of 2,000 Mark annually to Freund, who had to spend this money to hire a research assistant and to cover the running expenses of his research laboratory. In turn, all product or process innovations discovered had to be presented to Merck before publication in a scientific journal. All innovations became the joint property of Merck and Freund and the firm decided on the commercial exploitation of the invention. If the innovation seemed to become a commercial success, Merck had to produce and distribute it on an industrial scale. Freund, on the other hand, had to support the diffusion of knowledge about the innovation in the scientific community, to fill the patent in Merck's name, and to defend the patent against infringements of third parties. In addition, all profits were shared between Merck and Freund. For each product, the exact profit share of the two parties depended on the degree of patent protection. In general, Freund's share varied between 15 and 50 percent of the accounting profit. 37 In the case of the blockbuster Stypticin, for example, Freund's profit share was 30 percent of the net profit, indicating that the patent was not water-proof. 38 One result of the product-specific profit sharing was that Merck kept product specific accounts for up to 80 products during the pre-World War I period. These accounts contain information about revenues, production costs, and marketing costs. More specifically, the production costs included the running expenses for chemicals, heating material, wages, etc., as well as information about depreciation (capital costs) for the capital stock used for the production of a single drug. tion since then the contract closed with Knoll had to be adapted. 43 Consequently, the profitsharing agreement between Freund and Merck remained in force. 44 One key responsibility of outside inventors was the protection of the patent against infringements by competitors. As a matter of course, a successful product like Stypticin encouraged competing firms to develop similar products. The success of the drug is clearly visible in output and profit figures: the amount sold rose from 11.2 kg in 1897 to 187.6 kg in 1902; productions costs declined from 253 311 Mark in 1902. 45 Already in 1896, Merck had expected that the Stypticin patent was vulnerable and fixed Freund's share in profits at 30 percent, well below the maximum of 50 percent agreed upon in the Freund-Merck research contract for a water-proof patent, but also much higher than the minimum share in profit of 15 percent. In January 1903, Merck's patent was bypassed by the German pharmaceutical company Knoll & Co., which received a patent for a close substitute, Stypta. Martin Freund filed an objection against Knoll's patent at the Imperial Patent Office and a long-lasting legal dispute was fought between Freund and Merck, on one side, and Knoll and Dr. Vieth -the inventor of Knoll's product Stypta -on the other.
After three years of conflict, Knoll approached Merck to close a market-sharing agreement for Stypticin and Stypta. 46 Knoll proposed a profit-sharing agreement allocating at least two-thirds of the joint profits of both firms to Merck. If the profits generated by Merck were higher than two-thirds of the joint profits, Merck would not transfer any profits to Knoll. This proposal indicates that Knoll's patent most likely infringed Merck's patent. Moreover, Knoll asked Merck to close the agreement very soon since the Patent Office expected an elaboration of Knoll's patent within two weeks. Soon, Merck regarded Knoll's proposal with favour and agreed to withdraw its patent litigation after signing a profit-sharing agreement. The two firms negotiated the details of the market sharing agreement during the following two months and finally signed a contract, which was valid from 1 July 1906. 47
Beyond the long-term research co-operation with university professors, Merck bought many inventions from university professors as well as from free inventors. 48 Merck's activity on the market for innovations went far beyond these acquisitions of blockbuster drugs. The company bought, among many others, inventions for the production of dental cement 52 , the cost-efficient production of hydroquinone 53 , the manufacture of the pneumococcus serum Jequiritol 54 , the manufacture of anthrax sera 55 , and the production of the cinnamic acid product Zebromal 56 . A count of the product and process innovations highlighted in the annual reports of Merck's scientific laboratory shows that 44 percent of all product innovations -not all innovations discussed in the reports were commercially or technically successful -had their origin in university laboratories, 28 percent were prepared by free inventors, and only 28 percent were made in-house. Altogether, close relationships with university researchers were the most 
IV. In-house R&D
Merck's in-house research capacities were rather unimportant for the generation of new products. Nevertheless, several important tasks were fulfilled by Merck's researchers: they tested the product innovations offered by outside inventors, they scaled the production of new drugs and chemicals up from laboratory conditions to industrial production units, they tested the quality of inputs and of outputs, and they continuously improved the production processes. Challenging for the management was that Merck's in-house R&D capacities were scattered over different departments of the company. First of all, Willy Merck, co-owner of the firm and head of the production department, was an active researcher. Moreover, subordinate managers in the production department, in particular Carl Scriba, were often trained chemists with an interest in process optimization. Furthermore, chemists and pharmacists were employed in the control laboratory, the scientific information department, the bacteriological department, and -last but not least -the central research laboratory, which was established in 1898. 57 Furthermore, the research-related organisational units did not have well-defined areas of research, but intersected on many themes.
The control laboratory tested the quality of inputs delivered to Merck and of the outputs to be shipped to customers. In addition, it traced the origin of customers' complaints regarding product quality. During the business year 1897/ 98, for example, 9,638 preparations were evaluated in the control laboratory. At the time, two trained chemists, Dr. Braun and Dr. Neubert, between six and eight blue-collar workers, and one white collar worker were employed in the laboratory. 58 Moreover, it was involved in process optimization, a task also fulfilled by the production units and the central scientific laboratory.
The scientific information department, established in 1888, was mainly responsible for the information of the public about the latest innovations and of available products in pharmacy. The information was circulated using 'Merck's Jahresberichte' (Merck's digest), a booklet published in several languages and distributed all over the World. 59 The 1898 edition of Merck's digest was, for example, published in four languages (German, English, French, and Russian) and distributed in 27,000 copies to customers and scientists worldwide. The production of this report was the main task of Dr. Paul Zipperer, head of the scientific information department. Moreover, Zipperer, a clerk and a part-time chemist, were responsible for responding to scientific questions arising from the departments of the company, from customers, and from outside scientists. In 57 Therefore, Merck established a centralized research unit long before the foundation of its pharmaceutical research laboratory in 1927.
58
MRO F3/2a. 59
The following discussion is based on the review of activity of this department during the years 1888-1899, published in Merck's internal report for the business year 1898/ 99. MRO F3/3a.
1898, for example, 420 scientific correspondences with customers and outside researchers were handled and 2,175 enquiries from the various departments of the company were answered. Furthermore, the department organized the scientific library as well as the circulation of 56 scientific journals inside the company. Finally, members of the scientific information department supported the other laboratories and tested 48 drugs and made 40 experiments.
Bacteriological research was conducted at Merck since 1895 in the bacteriological production department headed by Dr. von Buisson. In addition, in August 1900 the bacteriological research laboratory headed by Dr. Landmann was established. Three years later, a new head of bacteriological research was hired: Wilhelm Eicholz, who earned his PhD in chemistry in 1901 from Emil Fischer. Eichholz was one of the longest-serving researchers at Merck and he stayed at the firm until his death in 1927. 60 His most important contributions were his participation in the Jodipin research and his invention of a dysentery serum in 1906. 61 The main tasks of the bacteriological research laboratory were the quality control of the products of the bacteriological production units as well as research regarding tubercle, typhus, and diphtheria. However, the resources for research were rather limited. For example, resources devoted to the development of the first bacteriological drug, Tuberculol, were just 23,216.37 Mark, spent over a period of eleven years. 62 Furthermore, Dr. Landmann was part-time delegated to the bacteriological production department. Moreover, the research unit was involved in quality control. For instance, 105 samples of the production department were investigated in the bacteriological research laboratory during 1900/ 01. 63 Nevertheless, in 1902, sera fighting tubercle, pneumococcus, and streptococcus were launched, followed by a diagnostic drug for typhus one year later. 64 Later on, research regarding diphtheria, typhus, and streptococcus was in the focus of the laboratory's staff. 65 Parallel to the bacteriological research conducted in Darmstadt, a bacteriological research unit was established in co-operation with Professor Sobernheim in Halle. Merck installed a research unit in Halle, directed by Sobernheim and staffed with Merck's own researcher, Dr. Burow. Burow started his research in May 1902 and worked for Merck until May 1911. 66 In particular, research in and production of an anthrax serum was conducted in Halle.
The central scientific laboratory, headed by the chemist Dr. Alexander Ehrenberg, was founded in 1898 by combining the departments for synthetic analysis, the analytical laboratory, the electro-chemical laboratory, the patent office, and the marketing department. 67 Already one year later, the central research laboratory was re-organized by dividing it into four sub-units: (i) the operations laboratory; (ii) the experimental laboratory; (iii) the electro-chemical department; (iv) the office for patents and marketing. This organisational structure remained in place at least until World War I.
Dr. Holzinger, the first staff member of the operations laboratory, improved the blueprints for new products from a laboratory scale to an industrial scale. Moreover, many new products were first produced and sold by the operations laboratory. Production was handed over to the production department when the process was fully developed. The experimental laboratory, staffed first by Dr. Kassner and Dr. Schnerr, had three main tasks. First, it checked inventions offered to Merck by outside inventors regarding the applicability on an industrial scale; second, it improved established production processes; third, it developed new products. The electro-chemical laboratory, staffed with Dr. Pip from 1898 onwards, participated in the research projects of the operations and experimental laboratory by applying electro analysis. The office for patents and marketing, finally, was responsible for safeguarding Merck's inventions, monitoring the patenting activities of competing firms, and circulating Merck's research results among scientists, users, and customers. In this office, Dr. Mennel was responsible for patents and Dr. Rahn for marketing. 68
The Merck's central research laboratory main task was the 'D' part of R&D, i.e., the optimization of production processes for large-scale production. This function can be quantified by counting the process innovations discussed in the annual reports of Merck's scientific laboratory: 88 percent of all process innovations can be ascribed to in-house researchers, whereas only six percent each originated from university researchers and free inventors.
The annual reports of the laboratory also include numerous case studies for process optimisation. For example, Albert Ladenburg, professor for chemistry in Breslau, demonstrated in 1894 the 68 MRO F3/4a. electro-chemical reduction of pyridine to piperidine. One of the first tasks of Dr. Pip, head of the electro-chemical research unit, was the adaptation of Ladenburg's method to an industrial scale. He succeeded soon and generated piperidine at a cost of 70 Mark per kg, 50 Mark per kg less than the original method. In addition, an optimized arrangement of the production process and the use of a modern filter press reduced the costs further to 50 Mark per kg. Merck's researcher proposed to the management of the firm that the knowledge about the new substance should be circulated in universities. Then, some technical or medical use of piperidines was expected to be found soon. 69 Indeed, some time later, piperidine became an important intermediate in the synthesis of drugs.
Another example for process development relates to the research concerning the barbiturate Veronal, invented in 1903 by Fischer and von Mehring, who were outside researchers for Bayer and Merck, respectively. Consequently, this first barbiturate was produced by Bayer and Merck using very similar methods. Merck soon figured out that the theoretical derivation and small-scale laboratory production of this barbiturate were insufficient for industrial production. Consequently, Merck hired two new researchers, Dr. Klein and Dr. Knell, to work exclusively on Veronal. The first major problem was the immense demand for the new drug, making large-scale production inevitable. Before the launch of the new drug, Merck estimated an annual demand of 500 kg. Yet, the production capacity had to be expanded to 5,000 kg per annum within the first year and a further increase to 10,000 kg seemed possible if the production unit was used 24 hour a day. 70 During the following year, Veronal-related research capacities at Merck were increased further as Fischer's former research assistant Dr. Wolfes was hired by the company. He was worth his money, since he substantially improved the use of alcohol in the production process. Thereby, he increased the rate of yield from 38 percent to 60 percent. Moreover, it seemed possible to increase the rate of yield to 70 percent. Nevertheless, Dr. Beckh, another researcher at Merck, reverse engineered the method used by Bayer and figured out that Bayer's rate of yield was even higher. Nevertheless, Merck's method was less expensive at the actual input prices. 71 Naturally, Veronal's high profitability -the profit-turnover ratio was 35 percent in 1903/ 04attracted market entrants. For example, Schering and Hoechst earned money on a Veronal-like drug using a method that had just one-third of the rate of yield of the MRO F3/9c. During 1905/ 06, the situation had stabilised and the prominence of Veronal in the research laboratory declined. Merck's method was nearly as efficient as the one used by Bayer. In addition, Hoechst's production was eliminated by a decision of the patent office. Schering's production was interrupted by a decision of the patent office. MRO F3/10c.
The third example of process optimization concerns the production of tannins, an important raw material for the production of herbal pharmaceutics. 73 During the mid-1890s, Merck's position in this market was endangered by a new process developed by Schering. To counter this attack, Merck experimented with five new processes for the production of tannins. The six input factors had to be composed in a way that the four different types of outputs were generated in a profitmaximizing way at given market prices. In a first step, a new method was theoretically developed. This new method reached a rate of yield of 72 percent, much better than the 64 percent of Merck's old method and above the rate of yield of Schering's method. In a second step, the theoretical results had to be applied in practice. Between January and April 1897, Merck's chemists tried five different modes of production. In practice, the new method had a rate of yield of 70.23 percent, less than the model predicted for Merck's method, but higher than the old process. As a result, the new process resulted in a decline of production costs from 2.60 Mark per kg to 2.20 Mark per kg of tannin. The fact that the decline in production costs was relatively higher than the increase of the rate of yield is striking. This indicates that Merck's researcher did not only improve the process, but that they also optimized the structure of input factors in view of current prices. Moreover, the researchers expected declining costs due to learning effects of the workers and due to a new design of the manufacturing facility, which was expected to reduce the loss of ether, an input factor. Consequently, the chemists projected a decline of production costs to 2.10 Mark per kg, nearly 20 percent less than the unit costs of the old process. 74
In-house product development, on the other hand, mostly failed. A striking example is the production of vanillin and heliotropine, two basic materials for perfume production. In 1874, the first chemical production of vanillin using the sap of spruce bark was realized by the German chemists Wilhelm Haarmann and Ferdinand Tiemann, who founded a firm -Haarmann's Vanillin-Fabrik -to exploit the patent. However, it took more than a decade and the invention of vanillin production using eugenol in 1891, to make the chemical production of it a big commercial success. A few years later, Merck decided to enter this market. During the business year 1897/ 98, a new, four-step production method for vanillin was developed by Merck's researchers. The first step was the relocation of eugenol to iso-eugenol using a new method, which was not in conflict with existing patents. However, the new method was not revolutionary enough to get a patent. In the second step, the iso-eugenol was acetylated and the resulting product was -in step three -oxidated to acetvanillin. Finally, vanillin was separated from acetvanillin. Moreover, economies of scope could be realized since the same instruments and machines used for the production of vanillin could also be used in the production of heliotropine. 75 One year later, Merck received a patent for step two of its new method. Furthermore, large-scale experiments were conducted to get data for the estimation of future production costs and to optimise the production process. In addition, two investment plans were presented to the management of the firm. An entirely new facility for the production of vanillin and heliotropine would cost about 40,000 73 The relevance of tannins for Merck can be shown using revenue and profit figures for 1908 and 1909. During these two years, tannins generated a turnover of more than 700,000 Mark (about 4 percent of total turnover) and profits of more than 110,000 Mark. MRO H5/9a. 74 MRO F3/1a. 75 MRO F3/2c.
Mark, whereas the conversion of existing facilities would be possible at a cost of only 16,000 Mark. The latter plan was agreed upon and the production on an industrial scale was bound to start during 1900. 76 However, it turned out that Merck's method had a much lower rate of yield than expected from the laboratory experiments. Simultaneously, the market price of vanillin declined substantially. Consequently, Merck was not able to compete on the product market. Nevertheless, the management decided to continue the production since substantial fixed costs had already been sunk. 77 Yet, prices for vanillin and heliotropine declined further and the production was stopped in 1901, about one year after Merck's entry into the market. 78
At regular intervals, shortages of resources devoted to R&D were discussed in the annual reports of the central research laboratory. For example, resources were temporarily shifted from the central research laboratory to the production units. 79 Another example of resource constraints concerned the electro-chemical department. This department should have been equipped with many complex installations, but the necessary office and laboratory space was sometimes unavailable. 80 A final example concerns the experimental laboratory. Due to missing office space in the laboratory, no new scientists were hired in 1902 after the promotion of Dr. Immel and Dr. Seuffert into the production department. 81 Even one of the core activities of the central research laboratory, the protection of drugs using the patent system, was sometimes not completely fulfilled.
The report for 1899/ 1900 states, for example, that the experiments to extend the patent protection of Merck's cocaine processes were of only secondary importance for the researchers. 82 Furthermore, the use of patent lawyers was restricted as far as possible to save money, and the corresponding tasks were performed in-house by Merck's patent department. 83 The 1908 report stated that the operations laboratory received, after several years of waiting, a large centrifugal and a large agitating tub. The head of the scientific research laboratory, Dr. Beckh, claimed that this delay had negative consequence, for the scientific work as well as for the whole company: "Es kann nicht scharf genug auf den Schaden hingewiesen werden, welcher nicht nur der Wissenschaft, sondern auch der Fabrik durch ein derartiges Gebahren entsteht, und es ist zu hoffen, daß die jetzt vorhandenen Anfänge einer Versuchsapparatur für Fabrikationszwecke dem Laboratorium dauernd erhalten bleiben." early 20 th century prescribed that chemists were initially hired for one year, followed by an openended contract with a period of notice of three months. The annual fixed income varied between 2,400 Mark and 4,500 Mark. All inventions made were automatically transferred to Merck, and most contracts did not contain a profit-sharing agreement. 85 In this respect, Merck differed from Bayer, where the researchers received a share in product specific profits of up to five percent (Wimmer, 1994: 124-126; Meyer-Thurow, 1982: 373-375 ). Yet, in-house researchers at Bayer only received this profit share for new products and not for process improvements of external inventions. Therefore, Bayer's in-house research staff impeded the acquisition of externally developed products (Wimmer, 1994: 140-141 […] By perfecting our operational methods we will most probably be able to maintain most of our major products on the same high standard, as well as holding our key markets; yet, this does not inevitably mean PROGRESS. We must still bear in mind that the real large-scale chemical industry, the dyestuff and acid factories, are gradually looking into producing the very same key substances we make, as a result of consistently growing competition. Using the same production methods as we do, they will no doubt soon be able to underbid us in these products, due to cheaper raw materials, thus attracting the consumer. For this reason, the ground should be prepared for new innovations as soon as the time is right -not just some unpromising odds and ends, but a few good specialist products. Then, other new branches should be taken on board. This would provide a guarantee for sustainable cost-effectiveness as a result of an increased market area and demonstrable usefulness."
Moreover, Dr. Beckh asked for better co-operation between chemists and medical scientists, as well as for intensified co-operation with university researchers. In particular, the scientific information department should improve the flow of information from practioners and university researchers to the members of the central research laboratory. Only when these pre-conditions are met, the central research laboratory could focus on the most important research topics. 87
V. Conclusion
During the 1880s and 1890s, traditional, alkaloid-based pharmaceutical research was challenged by the bacteriological revolution and by the discovery of dyestuff-based drugs. In addition, the latter development caused the market entry of dyestuff producers on the market for pharmaceuticals. Consequently, product market competition intensified substantially at the turn of the 20 th century. Moreover, some dyestuff producers -especially Bayer -started systematic research to discover new drugs. Thereby, the traditional trial-and-error approach of alkaloid-based pharmaceutical research used by incumbent producers like Merck came under pressure. Furthermore, the foundation of the state-sponsored health insurance in Germany during the 1880s and the modification of the German patent law in 1891 increased the demand for drugs and enhanced the possibilities to appropriate profits from patent-protected products. Finally -and exceptionally for the family-owned firm Merck -a new generation of family members took over the management of the firm during the 1880s and 1890s. Jointly and severally, the period between 1890 and 1913 was challenging for Merck.
Merck responded to these multiple challenges by adapting its research strategy and organisation. First, a significant number of long-term research co-operations were initiated during the 1890s. In this regard, Merck's strategy was similar to the one used by Hoechst, one of the large dyestuff producers entering the market for pharmaceuticals during the 1880s. Nearly all products launched by these firms were developed by university researchers, who were connected to the firms via long-term contracts. During the early 1890s, Bayer followed a similar strategy. Yet, at the turn of the century its in-house research capacities were sufficient to develop a continuous flow of new products. Schering, like Merck a traditional pharmaceutical company, was, on the 
